hengrui glp 1 Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 | Tue, 07/15/2025 Hengrui and Kailera report best-in-class
Pay in 4 interest-free payments of $5.44 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5







/assets/production/practices/fd8b98fb7b6456ee1d87467e7a35b773cd825a78/images/2787496.jpeg)



/assets/images/provider/photos/2786113.jpeg)















